ALK B ALK-abello A/S Class B

ALK updates its full-year financial outlook

ALK updates its full-year financial outlook

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its preliminary results for Q3 is showing a 7% organic revenue growth, fuelled by a 52% increase in tablet sales. Therefore, the company is upgrading its earnings and cash flow outlook to DKK 350-400 million and approximately DKK 0, respectively, while narrowing its revenue growth outlook to around 8% organic growth.

Preliminary Q3 results show organic revenue growth in local currencies to DKK 772 million (739). This was achieved despite the continuing negative impact of COVID-19 on ALK’s legacy business, predominantly in the USA where ALK estimates missed sales due to the pandemic of more than DKK 100 million for the full year. Earnings (EBITDA) in Q3 grew by 61% to DKK 58 million (36), due to savings, operational leverage and delayed R&D expenditure.

ALK’s outlook update is as follows:

  • Organic revenue growth is expected at around 8% equating to approximately DKK 3.5 billion (previously towards the lower end of 8-12%).
  • Operating profit (EBITDA) is now expected to be DKK 350-400 million (previously 300-350).
  • Free cash flow is now expected at approximately DKK 0 million (previously negative ~200), reflecting the higher earnings and a positive change to working capital.

ALK will detail the revised full-year outlook in its nine-month interim report (Q3), which will be published Wednesday 11 November 2020, following which, the company will host a teleconference for analysts and institutional investors at 1.30 p.m. (CET).

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Jeppe Ilkjær, mobile

This information is information that ALK-Abelló A/S is obliged to make public pursuant to the EU Market Abuse Regulation.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen. Find more information at .

Attachment

EN
05/11/2020

Underlying

ALK BALK-abello A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-abello A/S Class B

Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Expecting solid start to the year

We expect a solid Q1 report, with likely c11% organic growth as well as good margin progress supporting the 2025 guidance. Based on its footprint, we see minimal effect in case of tariffs on pharmaceuticals, with the biggest risk coming from potential reciprocal ones from Europe. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
04/25/25 April 25, 2025 1 EN
Free Trial
ALK B ALK-abello A/S ...

Alk-Abello A S: 1 director

A director at Alk-Abello A S bought 1,606 shares at 155.680DKK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

ALK B ALK-ABELLO A/S CLASS B
02/24/25 February 24, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Sales trump one-offs in Q4

While one-off costs took the initial focus (albeit broadly pre-warned), a solid underlying performance in Q4 was anchored in the important European tablet sales, which exceeded expectations. We find the 2025 guidance in line with expectations, but see upside risk to consensus on the top line given strong momentum in tablet sales in Europe. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
02/19/25 February 19, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Expecting strong year end

We expect a strong Q4, with c12% organic revenue growth YOY, but the EBIT margin to be under pressure from well flagged one-offs related to optimisation initiatives and revision of its Chinese plans. We expect the 2025 guidance to be in line with expectations and its long-term strategy announced last year for >10% organic revenue growth and a c25% EBIT margin. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
02/13/25 February 13, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Solid momentum reaffirmed

We find ALK’s solid momentum reaffirmed with the strong Q3 results, where higher European tablet sales more than offset the softness in SCIT/SLIT-drops. We believe the results also confirmed continued profitability improvement, leaving ALK on track to meet its 2025 EBIT margin target of c25% and in a position of strength to invest in growth opportunities, with the Neffy deal as a good example. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
11/14/24 November 14, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch